Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Slides:

Advertisements

Similar presentations

Candidate Vaccine Strains and Potency Reagents for Influenza Season

Advertisements

Candidate Vaccine Strains and Potency Reagents, Season Rajesh K. Gupta, Ph.D. Deputy Director, Division of Product Quality OVRR, CBER, FDA Prepared.

Vaccines and Related Biological Products Advisory Committee 18 February 2009 Topic 2: Considerations and Implications for adding two B Strains to the Seasonal.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Adriana Weinberg, MD University of Colorado Denver.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

U.S. Surveillance Update Anthony Fiore, MD, MPH CAPT, USPHS Influenza Division National Center for Immunizations and Respiratory Disease Centers for Disease.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA’s website for reference purposes only.

Medical Technology Department, Faculty of Science, Islamic University-Gaza MB M ICRO B IOLOGY Dr. Abdelraouf A. Elmanama Ph. D Microbiology 2008 Chapter.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 27 February 2013 The FDA CBER requested this annual.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/27/2013) Jerry P. Weir, Ph.D., Director.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/28/2014) Jerry P. Weir, Ph.D., Director.

Influenza Vaccine Manufacturing Industry perspective for influenza vaccine supply VRBPAC, 28 February 2012 The FDA CBER requested this annual.

NS 2 Lipid Bilayer NA (Neuraminidase) HA (Hemagglutinin) M 2 (Ion channel) M 1 (Matrix protein) NP (Nucleocapsid) PB1, PB2, PA (Transcriptase complex)

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/25/2011) Jerry P. Weir, Ph.D., Director.

Vaccines and Related Biological Products Advisory Committee Presentation on Sanofi Pasteur’s H5N1 Vaccine Andrea N. James, M.D. Senior Medical Officer.

Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.

Martha Thompson, MPH Viral Isolation Team Leader Medical Virology Group Laboratory Services Section TX DSHS Influenza Surveillance Viral Isolation Laboratory.

Pandemic (H1N1) 2009 Influenza Vaccine Manufacturing Considerations Vaccines and Related Biological Products Advisory Committee (7/23/2009) Jerry P. Weir,

Influenza Vaccine Manufacturing Industry Perspective Tony Colegate Novartis Vaccines and Diagnostics Prepared by PhRMA Vaccine Technical Committee for.

VRBPAC 25 February 2011 Influenza Vaccine Manufacturing Industry Perspective for Vaccine Supply.

Review and Discussion Time line courtesy of:

“FluBlØk: A Recombinant Hemagglutinin Protein Vaccine for Influenza” Manon Cox VRBPAC February 27, 2007 A Vaccine Company for the 21st Century “Making.

Influenza Branch Division of Viral and Rickettsial Diseases National Center for Infectious Diseases Centers for Disease Control and Prevention Atlanta,

Texas Influenza Surveillance Lesley Bullion Influenza Surveillance Coordinator Infectious Disease Control Unit.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Vaccines and Related Biological Products Advisory Committee Meeting July 23, 2009 Pandemic Influenza A (H1N1) Virology Update Nancy Cox, PhD Alexander.

1 Overview of the Division of Viral Products February 28, 2014 VRBPAC Discussion of the August 28, 2013 Site Visit for the Laboratory of Respiratory Viral.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE USPHS INFLUENZA VIRUS VACCINE STRAIN SELECTION

Influenza Influenza Virus magnified 100,000X. What is Influenza? Virus; causes chills, fever, sore throat, fatigue.

WHO Collaborating Centre for Influenza - Australia.

Options for Influenza Vaccine Composition Summary of Data Options with Pros and Cons.

Supplemental Digital Content 1 Hemagglutination-inhibition (HI) antibodies against A/New Caledonia/20/99 [H1N1], A/Wisconsin/67/2005 [H3N2] and B/Malaysia/2506/2004.

1 Approaches to Demonstrate Effectiveness of Vaccines for Prevention of Group B Meningococcal Disease Introduction Vaccines and Related Biological Products.

Update on Influenza Virus Surveillance Findings in 2008/09 Season in Northern Hemisphere Who Collaborating Center for Reference and Research on Influenza.

Influenza Virus Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products.

VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER Regulatory Approaches & Activities To Support Licensure of Pandemic (H1N1) 2009 Vaccine.

Influenza H1N1 Introduction. What is Influenza A H1N1?  Influenza virus  Family Orthomyxoviridae  2 important surface proteins  Haemagglutinin (H)

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products OVRR/CBER/FDA Prepared for Vaccines and Related Biological Products Advisory.

Samar Musmar,MD,FAAFP Vice Dean for Clinical Affairs An-Najah National University Faculty of Medicine Head, Medicine and Society Dep. Flu Vaccination in.

Influenza Branch VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE CBER, FDA February 16-17, 2005, Bethesda, MD Nancy COX, Ph.D. WHO COLLABORATING.

Developing a Vaccine to Protect Against Pandemic Influenza Public Statement by GlaxoSmithKline 27 February 2007.

Influenza Virus Vaccine Strain Selection Vaccines and Related Biological Products Advisory Committee (2/22/2010) Jerry P. Weir, Ph.D., Director.

1 IMMUNE CORRELATES OF PROTECTION AGAINST INFLUENZA A VIRUSES IN SUPPORT OF PANDEMIC VACCINE DEVELOPMENT FDA/NIH/WHO Public Workshop, December 10-11, 2007.

Novartis Vaccines - Influenza A H1N1v vaccine development Theodore F Tsai MD MPH July 23, 2009 DHHS supported influenza cell culture vaccine production.

Lisa Grohskopf, MD, MPH U.S. Influenza Surveillance Season National Center for Immunization & Respiratory Diseases Influenza Division U.S. Food.

Influenza Vaccine Responses Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee.

Options for Influenza Vaccine Composition Roland A. Levandowski, M.D. Division of Viral Products Prepared for Vaccines and Related Biological.

DoD Global Influenza Surveillance Program Sentinel Site Surveillance at AFIOH Sequence Analysis And Vaccine Effectiveness Overview Luke T. Daum, PhD, Molecular.

STATUS OF CANDIDATE VACCINE STRAINS AND POTENCY REAGENTS Zhiping Ye, M.D., Ph.D. FOOD AND DRUG ADMINISTRATION CENTER FOR BIOLOGICS EVALUATION AND RESEARCH.

INFORMATION FOR THE VACCINES AND RELATED BIOLOGICAL PRODUCTS ADVISORY COMMITTEE, CEBR, FDA February 27-28, 2007 WHO COLLABORATING CENTER FOR SURVEILLANCE,

1 Vaccines and Related Biological Products Advisory Committee Meeting FluBlok ® : Influenza Vaccine, Recombinant Hemagglutinin Applicant: Protein Sciences.

Carol Friedman, D.O. Associate Director for Adult Immunization Immunization Services Division National Center for Immunization and Respiratory Diseases.

Marketing Authorisation & Yearly Licence of Influenza Vaccines - „Mock-up” & Pre-Pandemic Influenza Vaccines Zsuzsanna Pauliny MD

Influenza Virologic Surveillance and Vaccine Strain Selection Xiyan Xu MD Deputy Director WHO Collaborating Center for Surveillance, Epidemiology and Control.

Figure 1. Antibody responses against homologous 2013 H7 virus in H7N9-infected patients. A, Serum samples from H7N9-infected patients were collected at.

Copyright © 2014 American Medical Association. All rights reserved.

Copyright © 2007 American Medical Association. All rights reserved.

U.S. Food and Drug Administration

CD154 Expression Is Associated with Neutralizing Antibody Titer Levels Postinfluenza Vaccination in Stem Cell Transplant Patients and Healthy Adults

Planning for Pandemic Influenza

NP sequence alignment of human H1N1 strains and phylogenetic analysis of representative NP from pandemic and seasonal H1N1 strains. NP sequence alignment.

J. -H. Lin, S. -C. Chiu, J. -C. Cheng, H. -W. Chang, K. -L. Hsiao, Y

Pulmonary vaccination induces a long-term immune memory response to antigen challenge. Pulmonary vaccination induces a long-term immune memory response.

RTA-specific serum IgG antibody titers and TNA in mice immunized with RiVax or RVEc. RTA-specific serum IgG titers after the second (A) or third (B) immunizations.

Presentation transcript:

Influenza Vaccine Responses Zhiping Ye, M.D., Ph.D. Division of Viral Products Prepared for Vaccines and Related Biological Products Advisory Committee 17 February

Vaccine Responses to Recent Influenza isolates Panels of sera obtained from influenza vaccinees were tested for their ability to inhibit heamagglutination of current influenza isolates Post-vaccination antibody titer of current virus isolates compared to vaccine strain of virus (bold) Lower titers (italic) indicate poor antibody inhibition of tested virus isolates 2

1. AUSTRALIA IAN BARR, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) WHO, AUSTRALIA ELDERLY A/WELLINGTON/01/04 (H3N2) B/JIANSU/10/03 2. EUROPE JOHN WOOD, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIBSC, ENGLAND ELDERLY A/NEW YORK/55/04 (H3N2) B/JIANGSU/10/03 3. JAPAN TAKATO ODIGARI, PH.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) NIID, JAPAN ELDERLY A/NEW YORK/55/04 (H3N2) B/SHANGHAI/361/02 4. STEFAN GRAVENSTEIN, M.D. ADULTS A/NEW CALEDONIA/20/99 (H1N1) EASTERN VIRGINIA ELDERLY A/NEW YORK/55/04 (H3N2) MEDICAL SCHOOL, PEDIATRIC B/JIANGSU/10/03 USA Serum Panels for Serologies 3

ANTIGENS FOR SEROLOGIES (H3N2) VACCINE STRAIN A/New York/55/04 X-157 REPRESENTATIVE CURRENT STRAINS A/Wisconsin/76/05 A/Hiroshima/52/05 A/Anhui/1239/05 A/Brazil/1742/05 A/North Carolina/13/05 A/Sydney/545/05 A/Lyon/21/06 A/Norway/28/06 A/Gunama/16/05 A/Nagasaki/50/05 4

HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT INFLUENZA VACCINE PEDIATRIC POPULATION 5

HI ANTIBODY RESPONSES TO THE H3N2 COMPONENT INFLUENZA VACCINE ADULT POPULATION ( CBER ) 6

A/NEW YORK/55/2004 VACCINES SUMMARY TABLE (ADULT) VIRUSES WITH > 50% GMT REDUCTION 7

ANTIGENS FOR SEROLOGIES (B) VACCINE STRAIN B/JIANGSU/10/2003* REPRESENTATIVE CURRENT STRAINS B/FLORIDA/7/2004*B/KITAKYUSYU/5/2005* B/GANSU/9/2005*B/PHILIPPINES/1401/2005* B/MADAGASCAR/1509/2005*B/EGYPT/144/2005* B/MALAYSIA/2506/2004+ B/OHIO/1/2005+ B/GUANGONG/321/2005+B/ENGLAND/458/2005+ B/SINGAPORE/21/2005+ * B/YAMAGATA LINEAGE + B/VICTORIA LINEAGE 8

HI ANTIBODY RESPONSES TO THE B COMPONENT INFLUENZA VACCINE PEDIATRIC POPULATION 9

HI ANTIBODY RESPONSES TO THE B COMPONENT INFLUENZA VACCINE ADULT POPULATION (CDC) 10

B/JANGSU/10/2003-LIKE VACCINES SUMMARY TABLE VIRUSES WITH > 50% GMT REDUCTION (ADULT) 11

Influenza Vaccine Responses Summary Studies with sera collected after immunization with current vaccines show that: H1 –Representative recent viruses well inhibited (data not shown) H3 –A/WISCONSIN/67/2005 (H3N2)-like viruses less well inhibited compared to the vaccine strain B –B/YAMAGATA/16/88-lineage Representative recent viruses generally well inhibited compared to the vaccine strain –B/VICTORIA/2/87-lineage Representative B/Malaysia/2506/2004-like viruses poorly inhibited compared to the vaccine strain 12